GoAI
Get started
Edesa Biotech, Inc. logo

Edesa Biotech, Inc.

EDSA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.43

−$0.33 · -6.93%

Aug 21, 4:00 PM ET

Pre-market

$4.43

$0.00 · 0.00%

Aug 24, 4:00 AM ET

EDSA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

29

Expensive

Momentum

45

Neutral

Sentiment

64

Bullish

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA
CEO
Pardeep Nijhawan
Listed since
Jun 21, 2010
Employees
17

Market position

Day range

Current $4.43

52-week range

Current $4.43

Open
$4.90
Previous close
$4.76
Volume
156.24K
0.73× average
Average volume
214.97K
Average daily volume
Market cap
42.68M USD
Beta
1.08
Market reference 1
50-day average
$6.2058
-28.62% below average
200-day average
$5.1326
-13.69% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.23M USD
P/E (TTM)
-2.62×
P/B (TTM)
4.53×
P/S (TTM)
0×
EV / EBITDA
-0.46×
Earnings yield
-51.25%
Free cash flow yield
-52.22%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-57.71%
Return on assets
-53.11%
Return on invested capital
-63.54%

Financial health

Debt / equity
0×
Current ratio
10.67×
Altman Z-score
-5.11
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−7.91M USD-12.78%

Net income

−7.19M USD-16.46%
Income trends across reported periods−4.42M USD−11.42M USD−18.43M USD−25.43M USDOperating income, FY2021: −23.68M USDOperating income, FY2022: −18.37M USDOperating income, FY2023: −9.22M USDOperating income, FY2024: −7.01M USDOperating income, FY2025: −7.91M USDNet income, FY2021: −13.34M USDNet income, FY2022: −17.55M USDNet income, FY2023: −8.37M USDNet income, FY2024: −6.17M USDNet income, FY2025: −7.19M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −23.68M USD. Operating income FY2022 −18.37M USD. Operating income FY2023 −9.22M USD. Operating income FY2024 −7.01M USD. Operating income FY2025 −7.91M USD. Net income FY2021 −13.34M USD. Net income FY2022 −17.55M USD. Net income FY2023 −8.37M USD. Net income FY2024 −6.17M USD. Net income FY2025 −7.19M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold119.27K USD186.05K USD183.47K USD118.19K USD118.79K USD
Gross profit−119.27K USD−186.05K USD−183.47K USD−118.19K USD−118.79K USD
Research and development3.67M USD2.88M USD4.79M USD13.34M USD17.95M USD
Selling, general, and administrative4.24M USD4.13M USD4.43M USD5.04M USD5.73M USD
Operating expenses7.79M USD7.01M USD9.22M USD18.37M USD23.68M USD
Interest income2.56K USD153.5K USD289.85K USD63.52 USD11.17K USD
Depreciation and amortization119.27K USD186.05K USD183.47K USD118.19K USD118.79K USD
Operating income−7.91M USD−7.01M USD−9.22M USD−18.37M USD−23.68M USD
Net income−7.19M USD−6.17M USD−8.37M USD−17.55M USD−13.34M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 4 misses, 2 met estimates
Average EPS surprise
-7.60%
11 comparable reports
Latest EPS result
-0.6
Estimate -0.44 · Miss by 37.93%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.2-0.35-0.49-0.64Q1 '25MissQ2 '25MetQ3 '25BeatQ4 '25MissQ1 '26MetQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 14, 2025: actual -0.48, estimate -0.31, surprise -54.84%, Miss. Q2 2025, reported May 14, 2025: actual -0.3, estimate -0.3, surprise 0.00%, Met estimate. Q3 2025, reported Aug 8, 2025: actual -0.25, estimate -0.26, surprise +3.85%, Beat. Q4 2025, reported Dec 12, 2025: actual -0.32, estimate -0.27, surprise -18.52%, Miss. Q1 2026, reported Feb 13, 2026: actual -0.28, estimate -0.28, surprise 0.00%, Met estimate. Q2 2026, reported May 14, 2026: actual -0.49, estimate -0.24, surprise -104.17%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.6, estimate -0.435, surprise -37.93%, Miss. Q4 2026, reported Dec 11, 2026: actual —, estimate -0.49, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions
Brookline CapitalmaintainBuy

EDSA news

globenewswire.com

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for…

Read source
globenewswire.com

Edesa Biotech Announces Proposed Public Offering

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for…

Read source
globenewswire.com

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported…

Read source
globenewswire.com

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for…

Read source
globenewswire.com

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 11, 2023

1:7

Stock split

Effective Jun 10, 2019

1:6

Stock split

Effective May 7, 2018

1:7

Stock split

Effective Sep 2, 2015

1:10

EDSA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding EDSA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
418.2K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research EDSA

research.disclaimer